Top 20 Venture Capital Firms

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: Genetic Engineering and Biotechnology News (12/18/12)

"Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies?"

In order to start up a company, one must have capital, and for some companies, a venture capital firm may be the best source for it. Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies? Below is a list of top venture capital firms and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active "committed" capital from funds in use.

Genetic Engineering and Biotechnology News

Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion
Source: Streetwise Reports (04/08/2026)

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.

California Biotech Co. Advances Depression Drug Breakthrough
Source: Streetwise Reports (04/07/2026)

Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial
Source: Dr. Ananda Ghosh (04/07/2026)

H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough
Source: Streetwise Reports (04/02/2026)

Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.